Inflammatory Markers and Incidence of Hospitalization With Infection in Chronic Kidney Disease.


Journal

American journal of epidemiology
ISSN: 1476-6256
Titre abrégé: Am J Epidemiol
Pays: United States
ID NLM: 7910653

Informations de publication

Date de publication:
05 05 2020
Historique:
received: 10 05 2019
revised: 09 10 2019
accepted: 11 10 2019
pubmed: 2 11 2019
medline: 4 7 2020
entrez: 2 11 2019
Statut: ppublish

Résumé

Persons with chronic kidney disease (CKD) are at high risk of infection. While low-grade inflammation could impair immune response, it is unknown whether inflammatory markers are associated with infection risk in this clinical population. Using 2003-2013 data from the Chronic Renal Insufficiency Cohort Study (3,597 participants with CKD), we assessed the association of baseline plasma levels of 4 inflammatory markers (interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interleukin-1 receptor antagonist (IL-1RA), and transforming growth factor-β (TGF-β)) with incident hospitalization with major infection (pneumonia, urinary tract infection, cellulitis and osteomyelitis, and bacteremia and sepsis). During follow-up (median 7.5 years), 36% (n = 1,290) had incident hospitalization with major infection. In multivariable Cox analyses with each inflammatory marker modeled as a restricted cubic spline, higher levels of IL-6 and TNF-α were monotonically associated with increased risk of hospitalization with major infection (for 95th vs. 5th percentile, hazard ratio = 2.11 (95% confidence interval: 1.68, 2.66) for IL-6 and 1.88 (95% confidence interval: 1.51, 2.33) for TNF-α), while corresponding associations for IL-1RA or TGF-β were nonsignificant. Thus, higher plasma levels of IL-6 and TNF-α, but not IL-1RA or TGF-β, were significantly associated with increased risk of hospitalization with major infection. Future studies should investigate whether inflammatory pathways that involve IL-6 and TNF-α increase susceptibility to infection among individuals with CKD.

Identifiants

pubmed: 31673705
pii: 5602653
doi: 10.1093/aje/kwz246
pmc: PMC7306687
doi:

Substances chimiques

Biomarkers 0
Interleukin 1 Receptor Antagonist Protein 0
Interleukin-6 0
Transforming Growth Factor beta 0
Tumor Necrosis Factor-alpha 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

433-444

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR002548
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK060963
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007024
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024131
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000003
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000439
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK060990
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002240
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR029879
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061028
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000433
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK060984
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061021
Pays : United States
Organisme : NIDDK NIH HHS
ID : U24 DK060990
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK060980
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061022
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000424
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR016500
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM109036
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK060902
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002003
Pays : United States

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Circulation. 2003 Jan 7;107(1):87-92
pubmed: 12515748
J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S148-53
pubmed: 12819321
Kidney Int. 1999 Mar;55(3):1081-90
pubmed: 10027947
Annu Rev Immunol. 1998;16:27-55
pubmed: 9597123
Ann Epidemiol. 2013 May;23(5):291-3
pubmed: 23522903
Rheumatology (Oxford). 2000 Aug;39(8):870-4
pubmed: 10952741
Am J Respir Crit Care Med. 2005 Dec 1;172(11):1440-6
pubmed: 16166617
N Engl J Med. 1999 May 6;340(18):1398-405
pubmed: 10228190
Clin J Am Soc Nephrol. 2009 Aug;4(8):1302-11
pubmed: 19541818
Immunity. 2013 Dec 12;39(6):1003-18
pubmed: 24332029
Lancet. 2008 Mar 22;371(9617):987-97
pubmed: 18358926
Cytokine Growth Factor Rev. 2002 Aug-Oct;13(4-5):323-40
pubmed: 12220547
J Infect Dis. 1997 Nov;176(5):1293-302
pubmed: 9359731
Cell Biosci. 2012 Mar 15;2:9
pubmed: 22420375
Clin J Am Soc Nephrol. 2012 Dec;7(12):1938-46
pubmed: 23024164
Am J Kidney Dis. 2017 Jun;69(6):752-761
pubmed: 27884474
Clin Exp Immunol. 2003 Oct;134(1):120-6
pubmed: 12974764
Am J Kidney Dis. 2015 Jul;66(1 Suppl 1):Svii, S1-305
pubmed: 26111994
Am J Respir Crit Care Med. 2003 Dec 15;168(12):1462-70
pubmed: 12958055
Front Immunol. 2018 Jan 10;8:1960
pubmed: 29375577
J Clin Epidemiol. 2007 Apr;60(4):397-409
pubmed: 17346615
N Engl J Med. 2012 Jul 5;367(1):20-9
pubmed: 22762315
Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1399-1408
pubmed: 28818849
PLoS One. 2013;8(2):e56249
pubmed: 23457535
J Crit Care. 2013 Oct;28(5):549-55
pubmed: 23414982
Infect Immun. 1992 Oct;60(10):4245-52
pubmed: 1328056
Stat Med. 2010 Dec 10;29(28):2920-31
pubmed: 20842622
Nat Rev Rheumatol. 2016 Jan;12(1):49-62
pubmed: 26656660
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Clin Exp Nephrol. 2019 Apr;23(4):437-447
pubmed: 30178234
Curr Opin Pharmacol. 2009 Aug;9(4):447-53
pubmed: 19481975
Circulation. 2001 Feb 20;103(7):947-53
pubmed: 11181468
Nat Rev Rheumatol. 2017 Jul;13(7):399-409
pubmed: 28615731
Antioxid Redox Signal. 2014 Feb 20;20(6):1000-37
pubmed: 23992156
Am J Kidney Dis. 2019 Jul;74(1):23-35
pubmed: 30898360
Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1546-56
pubmed: 27340285
Clin Infect Dis. 2009 Oct 1;49(7):1025-35
pubmed: 19708796
Kidney Int. 2017 Mar;91(3):711-719
pubmed: 28017325

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH